Grifols (NASDAQ:GRFS) Shares Gap Down – Here’s Why

Grifols, S.A. (NASDAQ:GRFS)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $7.85, but opened at $7.58. Grifols shares last traded at $7.59, with a volume of 131,977 shares traded.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Price Performance

The stock has a market capitalization of $5.26 billion, a price-to-earnings ratio of 7.89 and a beta of 0.43. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a fifty day simple moving average of $8.27 and a two-hundred day simple moving average of $8.12.

Hedge Funds Weigh In On Grifols

Several hedge funds have recently bought and sold shares of GRFS. GAMMA Investing LLC boosted its holdings in shares of Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 1,135 shares in the last quarter. Signaturefd LLC lifted its position in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,153 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,546 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Grifols in the second quarter valued at about $89,000. Finally, Chesapeake Capital Corp IL bought a new position in Grifols in the third quarter valued at about $148,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.